您当前所在的位置:首页 > 产品中心 > 产品信息
Lucanthone_分子结构_CAS_479-50-5)
点击图片或这里关闭

Lucanthone

产品号 DB04967 公司名称 DrugBank
CAS号 479-50-5 公司网站 http://www.ualberta.ca/
分子式 C20H24N2OS 电 话 (780) 492-3111
分子量 340.48236 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 4403

产品价格信息

请登录

产品别名

标题
Lucanthone
IUPAC标准名
1-{[2-(diethylamino)ethyl]amino}-4-methyl-9H-thioxanthen-9-one
IUPAC传统名
lucanthone
商标名
Miracil D
Nilodin
Scapuren
Tixantone
Miracol
别名
Lucantona [inn-spanish]
lucanthone
Lucanthone monohydrochloride
Lucanthonum [inn-latin]
Lucanthone hydrochloride
Lucanthon
1-[[2-(Diethylamino)ethyl]amino]-4-methylthioxanthone
1-((2-(Diethylamino)ethyl)amino)-4-methylthioxanthen-9-one

产品登记号

CAS号 479-50-5
PubChem CID 10180
PubChem SID 46507260

产品性质

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved; investigational
Description One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.
Indication Intended for use as a radiation sensitizer in the treatment of brain cancer.
Pharmacology Although lucanthone has structural and biochemical similarities to Actinomycin D, it has no hematological or gastro-intestinal toxicity at clinically tolerated doses. In trials, Lucanthone was found to be safe, practical and effective and was proposed for use in clinical protocols for the treatment of cancer. The specificity of lucanthone in combination with radiation for the treatment of brain tumors arises from the fact that lucanthone acts preferentially on cycling cells (most of the normal brain cells are non-cycling) and the fact that lucanthone crosses the blood brain barrier efficiently.
Affected Organisms
Humans and other mammals
Absorption Orally available
References
Luo M, Kelley MR: Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res. 2004 Jul-Aug;24(4):2127-34. [Pubmed]
Del Rowe JD, Bello J, Mitnick R, Sood B, Filippi C, Moran J, Freeman K, Mendez F, Bases R: Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):89-93. [Pubmed]
External Links
Wikipedia

参考文献

  • Luo M, Kelley MR: Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res. 2004 Jul-Aug;24(4):2127-34. Pubmed
  • Del Rowe JD, Bello J, Mitnick R, Sood B, Filippi C, Moran J, Freeman K, Mendez F, Bases R: Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int J Radiat Oncol Biol Phys. 1999 Jan 1;43(1):89-93. Pubmed